^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    U16

    i
    Other names: U16, CD20 specific CAR T, CART-20, CAR T-20
    Associations

    News

    Trials
    Company:
    Central South University, Shanghai Unicar
    Drug class:
    CD20-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1year
    Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
    New P1/2 trial
    |
    IL6 (Interleukin 6)
    |
    CD20 positive • CD20 negative
    |
    cyclophosphamide • U16
    over1year
    Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphoma. (PubMed, Discov Oncol)
    The effective dose of CAR-T20 in mice starts from 1 × 10 per mouse, equivalent to a clinical dose of 5 × 10/kg. Together, our data support the clinical translation of CAR-T20 for R/R B-cell NHL patients.
    Preclinical • Journal • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    CD20 expression
    |
    U16